Jose Alfredo Correa Guerrero

Prof. Dr. Jose Alfredo Correa Guerrero

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
VEValeria Esquiaqui-Rangel
Valeria Esquiaqui-Rangel
ANAndrea Nuñez-Mejia
Andrea Nuñez-Mejia
JRJeisón Rambal-Torres
Jeisón Rambal-Torres
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Even when people with diabetes mellitus (DM) meet their cholesterol goals, they still face a higher risk of heart and blood vessel problems. One major reason is a particle called lipoprotein(a), or Lp(a), which is similar to LDL cholesterol. Raised levels of Lp(a) are inherited rather than caused by lifestyle. Lp(a) can build up in the body and make it easier for blood clots to form because it closely resembles a protein called plasminogen, reducing its ability to form plasmin that dissolves blood clots. At the same time, chemical changes like oxidation and glycation can make blood vessels more inflamed, adding to the risk. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast to RNA-based targeted agents (antisense oligonucleotides and siRNA [Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in Phase 2 clinical trials. In this review, we bring together findings from laboratory research and clinical studies, and highlight why it is important to measure Lp(a) levels—at least once in a person’s life, and especially in those with diabetes—to help doctors better assess risk and plan more effective treatments. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.

Verified
Journal Article
Open access
PDF file
EOElber Luis Osorio-Rodriguez
Elber Luis Osorio-Rodriguez
Jose Alfredo Correa GuerreroJose Alfredo Correa Guerrero
Jose Alfredo Correa Guerrero
DBDayro Enrique Rodelo barrios
Dayro Enrique Rodelo barrios
MBMaría Bonilla-Llanos
María Bonilla-Llanos
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
CDCarmelo Dueñas-Castell
Carmelo Dueñas-Castell
Lung-protective ventilation and other experimental conditions raise arterial carbon dioxide tension (PaCO2) and alter pH. Short-term benefits are reported in non-infectious settings, whereas infection and/or prolonged exposure are typically harmful. This scoping review systematically maps immune-mediated effects of hypercapnia on innate immunity and alveolar epithelial repair. Scoping review per Levac et al. and PRISMA Extension for Scoping Reviews (Open Science Framework protocol: 10.17605/OSF.IO/WV85T; post hoc). We searched original preclinical studies (in vivo/in vitro) in PubMed, Web of Science, ScienceDirect, Cochrane Reviews, and SciELO (2008–2023). PaCO2 (mmHg) was prioritized; %Fraction of inspired Carbon Dioxide (%FiCO2) was recorded when PaCO2 was unavailable; pH was classified as buffered/unbuffered. Data were organized by context, PaCO2, and exposure duration; synthesis used heat maps (0–120 h) and a narrative description for >120 h. Mechanistic axes extracted the following: NF-κB (canonical/non-canonical), Bcl-2/Bcl-xL–Beclin-1/autophagy, AMPK/PKA/CaMKKβ/ERK1/2 and ENaC/Na,K-ATPase trafficking, Wnt/β-catenin in AT2 cells, and miR-183/IDH2/ATP. Thirty-five studies met the inclusion criteria. In non-infectious models, a “protective window” emerged, with moderate PaCO2 and brief exposure (65–95 mmHg; ≤4–6 h), featuring NF-κB attenuation and preserved epithelial ion transport. In infectious models and/or with prolonged exposure or higher PaCO2, harmful signals predominated: reduced phagocytosis/autophagy (Bcl-2/Bcl-xL–Beclin-1 axis), AMPK/PKA/ERK1/2-mediated internalization of ENaC/Na,K-ATPase, depressed β-catenin signaling in AT2 cells, impaired alveolar fluid clearance, and increased bacterial burden. Chronic exposures (>120 h) reinforced injury. Hypercapnia is a context-, dose-, time-, and pH-dependent double-edged modulator. The safe window is narrow; standardized, parallel reporting of PaCO2 and pH—with explicit comparisons of buffered vs. unbuffered hypercapnia—is essential to guide clinical translation.

21 August 2020 in Journal of Clinical Nephrology
Verified
Journal Article
Open access
PDF file
JRJorge Rico-Fontalvo
Jorge Rico-Fontalvo
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
MCMaria Ximena Cardona-Blanco
Maria Ximena Cardona-Blanco
VLVictor Leal-Martínez
Victor Leal-Martínez
EAEmilio Abuabara-Franco
Emilio Abuabara-Franco
LLLuis Lara
Luis Lara
Type 2 Diabetes Mellitus constitutes a major problem in public health worldwide. The disease poses a high risk of severe microvascular and macrovascular complications. Diabetic kidney disease is the most common cause of end-stage chronic kidney disease and contributes to the increasing morbidity and mortality associated to diabetes. Sodium-glucose contransporter-2 inhibitors (SGLT2 inhibitors) are the latest oral diabetic medications, which exhibit a great nephroprotective potential, not only by improving glycemic control, but also by glucose-independent mechanisms, such as decreasing blood pressure and other direct renal effects. We conduct a literature review based on the most recent scientific evidence with the goal to elucidate the postulated mechanisms of action of SGLT2 inhibitors in diabetic kidney disease, which are the base of the beneficial clinical effects that are seen in the condition.

17 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlberto Polo-Barranco
Alberto Polo-Barranco
CRCarlos Rebolledo-Maldonado
Carlos Rebolledo-Maldonado
VEValeria Esquiaqui-Rangel
Valeria Esquiaqui-Rangel
ANAndrea Nuñez-Mejia
Andrea Nuñez-Mejia
JRJeison Rambal-Torres
Jeison Rambal-Torres
EOElber Osorio-Rodríguez
Elber Osorio-Rodríguez
Diabetes mellitus (DM) is associated with a residual cardiovascular risk that persists even when lipid targets are achieved. Within this context, lipoprotein(a) [Lp(a)], an LDL-like particle of genetic origin with pro-atherogenic and antifibrinolytic properties, emerges as a key determinant in the progression of both microvascular and macrovascular complications. Its structural homology with plasminogen promotes thrombosis, while oxidative and glycation modifications amplify endothelial inflammation. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast with RNA-based targeted agents (antisense oligonucleotides and siRNA[Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in phase 2 clinical trials. This review integrates molecular mechanisms and clinical evidence, emphasizing the need to incorporate Lp(a) quantification (at least once in a lifetime, and selectively in DM) to refine risk stratification and guide intensive interventions. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.

20 July 2020 in Journal of Clinical Nephrology
Verified
Journal Article
Open access
PDF file
NGNehomar Pajaro Galvis
Nehomar Pajaro Galvis
JRJorge Rico-Fontalvo
Jorge Rico-Fontalvo
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
MBMaria Ximena Cardona- Blanco
Maria Ximena Cardona- Blanco
EAEmilio Abuabara-Franco
Emilio Abuabara-Franco
AAAna Alonso-Henriquez
Ana Alonso-Henriquez
Acute kidney injury is a common condition associated with high morbidity and short-term mortality. Its pathophysiology varies according to the numerous conditions associated with its genesis. Biomarkers allow detecting changes at the level of kidney function; therefore, they play an important role in the prevention, early diagnosis, therapeutic response and prognosis of acute kidney injury. The search for biomarkers for acute kidney injury began over 15 years ago; initially, only serum creatinine was available for diagnosis. However, throughout history, great advances have been made in research, which have allowed the finding of new biomarkers in order to improve the health and quality of life of patients. A narrative review of the literature is carried out on the basis of available scientific evidence to clarify the role and importance of biomarkers in the context of acute renal injury.

5 November 2020 in Revista Colombiana de Nefrología
Verified
Journal Article
Open access
PDF file
MRMaria Monterrosa Robles
Maria Monterrosa Robles
Jorge Rico FontalvoJorge Rico Fontalvo
Jorge Rico Fontalvo
RDRodrigo Daza-Arnedo
Rodrigo Daza-Arnedo
JOJosé Pérez Olivo
José Pérez Olivo
MBMaría Cardona Blanco
María Cardona Blanco
Jose Alfredo Correa GuerreroJose Alfredo Correa Guerrero
Jose Alfredo Correa Guerrero
Aunque en la actualidad la lesión renal aguda en mujeres embarazadas es una complicación poco común, esta se correlaciona con peores desenlaces maternos y fetales. Sus causas son múltiples y varían según el trimestre de presentación. Los cambios fisiológicos renales durante el embarazo hacen que los criterios diagnósticos de lesión renal aguda en la población general no sean fácilmente extrapolables a las pacientes obstétricas, por lo que la sospecha temprana y eltratamiento oportuno son fundamentales para evitar la progresión del daño renal y sus complicaciones sistémicas asociadas, incluidas las metabólicas, urémicas e hidroelectrolíticas.